117 related articles for article (PubMed ID: 30466759)
21. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Danylesko I; Shimoni A; Nagler A
Bone Marrow Transplant; 2012 Jan; 47(1):5-14. PubMed ID: 21478921
[TBL] [Abstract][Full Text] [Related]
22. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
Leon Rodriguez E; Rivera Franco MM; Perez Alvarez SI
Ann Hematol; 2017 Sep; 96(9):1525-1531. PubMed ID: 28691152
[TBL] [Abstract][Full Text] [Related]
23. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy.
Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Todorić-Zivanović B; Ostojić G; Tatomirović Z; Marjanović S; Malesević M
Vojnosanit Pregl; 2012 Jan; 69(1):37-42. PubMed ID: 22397295
[TBL] [Abstract][Full Text] [Related]
25. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
26. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
27. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
28. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
[TBL] [Abstract][Full Text] [Related]
29. Novel transplant strategies in adults with acute leukemia.
Paun O; Lazarus HM
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1319-39, ix. PubMed ID: 22093589
[TBL] [Abstract][Full Text] [Related]
30. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
31. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
33. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia.
Kurosawa S; Yakushijin K; Yamaguchi T; Atsuta Y; Nagamura-Inoue T; Akiyama H; Taniguchi S; Miyamura K; Takahashi S; Eto T; Ogawa H; Kurokawa M; Tanaka J; Kawa K; Kato K; Suzuki R; Morishima Y; Sakamaki H; Fukuda T
Bone Marrow Transplant; 2013 Sep; 48(9):1198-204. PubMed ID: 23562971
[TBL] [Abstract][Full Text] [Related]
34. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
35. The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
Yu CL; Zheng-Dong ; Qiao ZH; Wang JM; Huang-He ; Liang YM; Wu DP; Chen BA; Bai-Hai ; Shi BF; Sun WJ; Qiao JX; Guo M; Qiao JH; Sun QY; Hu KX; Huang YJ; Zuo HL; Huang XJ; Ai HS
Ann Hematol; 2017 Feb; 96(2):279-288. PubMed ID: 27864604
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
37. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
[TBL] [Abstract][Full Text] [Related]
38. The role of second transplants for leukemia.
Weisdorf D
Best Pract Res Clin Haematol; 2016 Dec; 29(4):359-364. PubMed ID: 27890260
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
40. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
Schneidawind C; Hagmaier V; Faul C; Kanz L; Bethge W; Schneidawind D
Ann Hematol; 2018 Dec; 97(12):2491-2500. PubMed ID: 30066039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
